Finding
ViiV’s Long-Acting Cabenuva Outperforms Daily Oral Therapy in Phase III Study
cabenuva, Daily, Standard of Care, Adherence (attribute), HIV, Participant, daily
Bayer Implements 95% Dividend Cut to Reduce Debt Amid CEO Bill Anderson’s Turnaround Plan
Bayer, Euro currency, Reduced, 95%
FDA Approves Xolair (Omalizumab) for Reducing Severe Outcomes from Multiple Food Allergies
Xolair, United States Food and Drug Administration, omalizumab, Hypersensitivity, Food, Reduced, Severe (severity modifier)
Eicos Sciences’ Aurlumyn: First FDA-Approved Treatment for Severe Frostbite Reduces Amputation Risk
Aurlumyn, Eicos, Amputation, Sciences’, iloprost, severe frostbite
Amgen’s obesity drug takes the weight off and may keep it off, too, early data suggest
Obesity, MariTide, Weight Loss, Source, Amgen’s, weight off
UPDATE: Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta
Cystic Fibrosis, Trikafta, vanza, Vertex, next-gen, Records
J&J’s Nipocalimab Demonstrates Positive Phase III and Phase II Results in Autoimmune Disorders
Nipocalimab, Sjogren’s Syndrome, Johnson and Johnson, Autoimmune Diseases, Myasthenia Gravis, Generalized, Clinical Research, Erythroblastosis, Fetal
Updated: Novo Holdings pays $16.5B to take Catalent private and sells three manufacturing sites to Novo Nordisk
Holdings, Nordisk, deal, Acquisition (action), Investments
Merck details win for Keytruda in bladder cancer after surgery
Keytruda, Malignant neoplasm of urinary bladder, Surgery specialty